Patient- and parent-initiated oral steroids for asthma exacerbations

Abstract

Asthma is a chronic condition of the airways affecting an estimated 334 million people worldwide (Global Asthma Report 2014). Direct treatment costs and indirect costs associated with lost productivity are substantial and are among the highest for non-communicable diseases (Global Asthma Report 2014). Asthma triggers may be allergic or non-allergic, resulting in airway inflammation, bronchoconstriction and limitation/obstruction of airflow. During a worsening of asthma symptoms (i.e. an exacerbation), which include tightness of the chest, wheeze and breathlessness, patients will typically exhibit reduced lung function (BTS/SIGN 2014).